Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis
Journal of Molecular Cell Biology · 2024
DOI: 10.1093/jmcb/mjad047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Cell Biology, 2024. Verfasst von Li-Bo Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Medical Research Institute, Zhongnan Hospital of Wuhan University, College of Life Sciences, Wuhan University, Wuh…. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms, Interferon Type I, Signal Transduction. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: State Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Estrogen receptor α (ERα) is an important driver and therapeutic target in ∼70% of breast cancers. How ERα drives breast carcinogenesis is not fully understood. In this study, we show that ERα is a negative regulator of type I interferon (IFN) response. Activation of ERα by its natural ligand estradiol inhibits IFN-β-induced transcription of downstream IFN-stimulated genes (ISGs), whereas ERα deficiency or the stimulation with its antagonist fulvestrant has opposite effects. Mechanistically, ERα induces the expression of the histone 2A variant H2A.Z to restrict the engagement of the IFN-stimulated gene factor 3 (ISGF3) complex to the promoters of ISGs and also interacts with STAT2 to disrupt the assembly of the ISGF3 complex. These two events mutually lead to the inhibition of ISG transcription induced by type I IFNs. In a xenograft mouse model, fulvestrant enhances the ability of IFN-β to suppress ERα+ breast tumor growth. Consistently, clinical data analysis reveals that ERα+ breast cancer patients with higher levels of ISGs exhibit higher long-term survival rates. Taken together, our findings suggest that ERα inhibits type I IFN response via two distinct mechanisms to promote breast carcinogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Medical Research Institute, Zhongnan Hospital of Wuhan University, College of Life Sciences, Wuhan University, Wuhan 430072, China.
- Frontier Science Center for Immunology and Metabolism, Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430072, China.
- Research Unit of Innate Immune and Inflammatory Diseases, Chinese Academy of Medical Sciences, Wuhan 430072, China.
ORCID-Profile: Zi-Lun Ruan, Jing Zhang
Förderung
- State Key R&D Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Cao, L. B., Ruan, Z. L., Yang, Y. L., Zhang, N. C., Gao, C., Cai, C., Zhang, J., Hu, M. M., & Shu, H. B. (2024). Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjad047
Vancouver
Cao LB, Ruan ZL, Yang YL, Zhang NC, Gao C, Cai C, et al. Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis. Journal of Molecular Cell Biology. 2024. doi:10.1093/jmcb/mjad047
BibTeX
@article{Cao2024,
author = {Cao, Li-Bo and Ruan, Zi-Lun and Yang, Yu-Lin and Zhang, Nian-Chao and Gao, Chuan and Cai, Cheguo and Zhang, Jing and Hu, Ming-Ming and Shu, Hong-Bing},
title = {Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis},
journal = {Journal of Molecular Cell Biology},
year = {2024},
doi = {10.1093/jmcb/mjad047}
}
EUVIMED